Prognostic Role of Tissue Plasminogen Activator in Coronary Artery Disease with or Without Aortic Valve Sclerosis
Authors' conclusion
Elevated circulating t-PA confers an increased risk for poor long-term clinical outcomes in stable coronary artery disease patients with AVSc.
Study context
- Population
- Consecutive stable angina patients with or without aortic valve sclerosis
- Participants
- 347 patients
- Exposure
- High vs low serum tissue plasminogen activator (t-PA) (above vs below median) in stable CAD with or without aortic valve sclerosis
- Aortic valve sclerosis (AVSc)n = 183
- non-AVScn = 164reference
- Outcome
- Composite of:
- CV death
- Rehospitalization due to HF
- Follow-up
- Up to 7 years
Methodological detailsconsecutive patients, Clinic evaluations every 6 months up to 7 years
- Consecutive patients
- Clinic evaluations every 6 months up to 7 years
Main finding
As reported in the abstract
Primary endpoint by t-PA level (subgroups by AVSc)
- AVSc: t-PA above median (>1840.68 pg/mL) more likely to meet primary and secondary endpoints
- P < 0.001
Observational data: associations, not effects.
Secondary outcomes
Serum t-PA level
P < 0.001
Prognostic performance of t-PA (AVSc)
- AUC-ROC
- 0.753
- Net reclassification index (t-PA + traditional risk factors)
- 0.857
- Integrated discrimination improvement
- 0.217
- AUC P < 0.001; NRI and IDI all P < 0.001
Original publication
Prognostic Role of Tissue Plasminogen Activator in Coronary Artery Disease with or Without Aortic Valve Sclerosis. ESC Heart Fail. Published 12 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →